RxDoctor Payments Data

David Geller

Los Angeles, CANPI 1154350528

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,799 of the $15,812 with a category attached, or 62.0%. 11 manufacturers reported payments, led by Ascendis Pharma Endocrinology Inc at 52.2% of the total. 2025 is the largest year on record at $8,970, more than ten times the $40 reported in 2021.

$15,812in general payments, 2019–2025

Across 30 payments — averaging $527.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ascendis Pharma Endocrinology Inc$8K
  • Pfizer$7K
  • Tolmar, Inc.$341
  • Novo Nordisk$125
  • AbbVie$64
  • Neurocrine Biosciences, Inc.$29
  • plus $118 from 5 others
$327,695in research payments, 2019–2025

Across 6 payments — averaging $54,616 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$328K

What the payments were for

  • Consulting fees$3,95025%
  • Speaking & faculty fees$9,79962%
  • Travel & lodging$1,0397%
  • Food & beverage$1,0246%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →